Coh-29

Coh-29

SCHEMBL31436912

O=C(Nc1nc(-c2ccc(O)c(O)c2)c(-c2ccccc2)s1)c1ccc(O)c(O)c1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PLTP P55058 8/20 0.61
▸ TOP1 P11387 1/20 0.58
▸ RRM1 P23921 2/20 0.55
▸ RRM2B Q7LG56 2/20 0.55
▸ ADORA2A P29274 2/20 0.53
▸ ADORA1 P30542 2/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ HPGD P15428 2/20 0.53
▸ MAPT P10636 3/20 0.52
▸ ADORA3 P0DMS8 1/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coh-29 SCHEMBL29424344 1.00 PLTP (0.61) PLTPTOP1RRM1RRM2BADORA2A
Coh-29 SCHEMBL10036527 1.00 PLTP (0.61) PLTPTOP1RRM1RRM2BADORA2A
SCHEMBL12940263 0.94 PLTP (0.59) PLTPTOP1RRM1RRM2BADORA2A
SCHEMBL10002075 0.81 PLTP (0.86) PLTPTOP1RRM1RRM2BSMN1; SMN2
SCHEMBL10002071 0.81 PLTP (0.63) PLTPTOP1RRM1RRM2BMAPT
SCHEMBL235132 0.81 ADORA2A (0.76) ADORA2AADORA1SMN1; SMN2KMT2AHPGD
SCHEMBL20343833 0.80 PLTP (0.48) PLTPTOP1RRM1RRM2BADORA2A
SCHEMBL12802354 0.80 L3MBTL1 (0.61) ADORA1SMN1; SMN2KMT2AHPGDMAPT
SCHEMBL2753880 0.80 SMN1; SMN2 (0.59) ADORA2AADORA1SMN1; SMN2KMT2AHPGD
SCHEMBL2753294 0.79 ADORA3 (0.74) ADORA2AADORA1SMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) 2025-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS DCK, DTYMK, TYMP PLTP 2865/4885TOP1 528/4885RRM1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback